JP2020536953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536953A5 JP2020536953A5 JP2020540680A JP2020540680A JP2020536953A5 JP 2020536953 A5 JP2020536953 A5 JP 2020536953A5 JP 2020540680 A JP2020540680 A JP 2020540680A JP 2020540680 A JP2020540680 A JP 2020540680A JP 2020536953 A5 JP2020536953 A5 JP 2020536953A5
- Authority
- JP
- Japan
- Prior art keywords
- dextromethorphan
- delivery device
- transdermal delivery
- adhesive
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 96
- 229960001985 dextromethorphan Drugs 0.000 claims description 96
- 230000037317 transdermal delivery Effects 0.000 claims description 52
- 239000000853 adhesive Substances 0.000 claims description 29
- 230000001070 adhesive effect Effects 0.000 claims description 29
- 239000012790 adhesive layer Substances 0.000 claims description 21
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 20
- 239000003961 penetration enhancing agent Substances 0.000 claims description 16
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 10
- 229960001404 quinidine Drugs 0.000 claims description 10
- 239000010410 layer Substances 0.000 claims description 9
- 230000001186 cumulative effect Effects 0.000 claims description 8
- 239000012848 Dextrorphan Substances 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- JAQUASYNZVUNQP-PVAVHDDUSA-N dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 claims description 6
- 229950006878 dextrorphan Drugs 0.000 claims description 6
- 239000013464 silicone adhesive Substances 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 4
- AKOAEVOSDHIVFX-UHFFFAOYSA-N Hydroxybupropion Chemical compound OCC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 AKOAEVOSDHIVFX-UHFFFAOYSA-N 0.000 claims description 4
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 2
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims description 2
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 claims description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical group C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 2
- 230000000954 anitussive effect Effects 0.000 claims description 2
- 229940124584 antitussives Drugs 0.000 claims description 2
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims description 2
- 229960003277 atazanavir Drugs 0.000 claims description 2
- 229960001058 bupropion Drugs 0.000 claims description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 2
- 229960002626 clarithromycin Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229960003914 desipramine Drugs 0.000 claims description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 2
- 229960005156 digoxin Drugs 0.000 claims description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 230000003166 hypermetabolic effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 229960001936 indinavir Drugs 0.000 claims description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 2
- 229960004130 itraconazole Drugs 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 229960002296 paroxetine Drugs 0.000 claims description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003634 pimozide Drugs 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229960002784 thioridazine Drugs 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 6
- 229930195729 fatty acid Natural products 0.000 claims 6
- 239000000194 fatty acid Substances 0.000 claims 6
- 229920001577 copolymer Polymers 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 5
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical group O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 4
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 3
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 3
- 239000005642 Oleic acid Substances 0.000 claims 3
- -1 fatty acid esters Chemical class 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 3
- 229920002367 Polyisobutene Polymers 0.000 claims 2
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 claims 2
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 claims 2
- 229920005573 silicon-containing polymer Polymers 0.000 claims 2
- 239000002356 single layer Substances 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 229920001756 Polyvinyl chloride acetate Polymers 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 230000010482 emotional regulation Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004380 tramadol Drugs 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- KWTWDQCKEHXFFR-UHFFFAOYSA-N 3-[1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical class CN(C)CC(C)C(CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-UHFFFAOYSA-N 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023136898A JP7609943B2 (ja) | 2017-10-04 | 2023-08-25 | デキストロメトルファン経皮送達デバイス |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568028P | 2017-10-04 | 2017-10-04 | |
| US62/568,028 | 2017-10-04 | ||
| US201862680182P | 2018-06-04 | 2018-06-04 | |
| US62/680,182 | 2018-06-04 | ||
| PCT/US2018/054178 WO2019070864A1 (en) | 2017-10-04 | 2018-10-03 | DEVICE FOR TRANSDERMAL DEXTROMETHORPHAN DELIVERY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023136898A Division JP7609943B2 (ja) | 2017-10-04 | 2023-08-25 | デキストロメトルファン経皮送達デバイス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536953A JP2020536953A (ja) | 2020-12-17 |
| JP2020536953A5 true JP2020536953A5 (https=) | 2021-11-04 |
Family
ID=65994772
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540680A Pending JP2020536953A (ja) | 2017-10-04 | 2018-10-03 | デキストロメトルファン経皮送達デバイス |
| JP2023136898A Active JP7609943B2 (ja) | 2017-10-04 | 2023-08-25 | デキストロメトルファン経皮送達デバイス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023136898A Active JP7609943B2 (ja) | 2017-10-04 | 2023-08-25 | デキストロメトルファン経皮送達デバイス |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11382869B2 (https=) |
| EP (1) | EP3691641A4 (https=) |
| JP (2) | JP2020536953A (https=) |
| KR (1) | KR20200062254A (https=) |
| CN (1) | CN111343980B (https=) |
| AU (1) | AU2018345723B2 (https=) |
| BR (1) | BR112020006723A2 (https=) |
| CA (1) | CA3078369A1 (https=) |
| IL (1) | IL273735B2 (https=) |
| MX (1) | MX2020003044A (https=) |
| TW (1) | TWI795446B (https=) |
| WO (1) | WO2019070864A1 (https=) |
| ZA (1) | ZA202001834B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795446B (zh) * | 2017-10-04 | 2023-03-11 | 美商神經治療股份有限公司 | 右旋美索芬(dextromethorphan)經皮輸送裝置 |
| IL296624A (en) * | 2020-03-30 | 2022-11-01 | Shinkei Therapeutics Inc | Transdermal delivery of dextromethorphan |
| CN117100750A (zh) * | 2020-07-20 | 2023-11-24 | 深圳信立泰药业股份有限公司 | 一种药物组合物及其应用 |
| AU2022207514A1 (en) * | 2021-01-18 | 2023-07-27 | Antecip Bioventures Ii Llc | Combination of an antidepressant and dextromethorphan for neuropsychiatric conditions |
| CN113720944B (zh) * | 2021-09-30 | 2023-04-28 | 珠海润都制药股份有限公司 | 一种氢溴酸右美沙芬硫酸奎尼丁胶囊含量的检测方法 |
| CN120322225A (zh) * | 2022-10-06 | 2025-07-15 | 新凯治疗有限公司 | 右美沙芬的经皮递送 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3020630B2 (ja) * | 1991-03-27 | 2000-03-15 | 三井化学株式会社 | 薬物投与用粘着剤 |
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| ATE246909T1 (de) * | 1994-03-07 | 2003-08-15 | Theratech Inc | Medikament enthaltende, adhesive, zusammenbaubare,transdermale abgabevorrichtung |
| SE9601528D0 (sv) * | 1996-04-23 | 1996-04-23 | Pharmacia Ab | Transdermally administered dextromethorphan as antitissue agent |
| TWI326214B (en) | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| DK1530469T3 (da) * | 2002-08-20 | 2009-05-04 | Euro Celtique Sa | Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist |
| CN1889994A (zh) * | 2003-12-10 | 2007-01-03 | 艾克若克斯Dds有限公司 | 伴随透皮或局部药物输送的不希望的效果的治疗方法 |
| US20060223786A1 (en) * | 2005-04-01 | 2006-10-05 | Smith David J | Transdermal pain control method and device |
| JP5666087B2 (ja) * | 2005-04-06 | 2015-02-12 | アダマス・ファーマシューティカルズ・インコーポレーテッド | Ｃｎｓ関連疾患の治療のための方法及び組成物 |
| CA2641392A1 (en) * | 2006-02-03 | 2007-08-16 | Avanir Pharmaceuticals | Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders |
| US20070248657A1 (en) * | 2006-04-25 | 2007-10-25 | Smith David J | Multi-compartment transdermal pain control device |
| CL2007002903A1 (es) * | 2006-10-09 | 2008-04-18 | Smithkline Beecham Corp | Composicion que comprende a) al menos un antagonista del receptor nicotinico a3beta4; y b) al menos un metabolito de la nicotina; y uso para reducir los sintomas de abstinencia de nicotina y/o el uso del tabaco. |
| WO2009021058A2 (en) * | 2007-08-06 | 2009-02-12 | Trinity Labortories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
| WO2010062690A1 (en) | 2008-10-30 | 2010-06-03 | Concert Pharmaceuticals Inc. | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury |
| BRPI1014886B1 (pt) * | 2009-04-24 | 2020-02-11 | Henkel IP & Holding GmbH | Polímeros acrílicos de silicone híbridos, seus métodos de preparação, adesivos e soluções de uma composição adesiva sensível à pressão compreendendo os mesmos. |
| US20140051718A1 (en) * | 2012-04-16 | 2014-02-20 | Antecip Bioventures Ii Llc | Compositions and Methods Comprising Celecoxib or Related Compounds and Dextromethorphan |
| CN110327338A (zh) * | 2013-11-05 | 2019-10-15 | 安泰赛普生物风投二代有限责任公司 | 包含安非他酮或相关化合物和右美沙芬的组合物和方法 |
| TWI795446B (zh) * | 2017-10-04 | 2023-03-11 | 美商神經治療股份有限公司 | 右旋美索芬(dextromethorphan)經皮輸送裝置 |
-
2018
- 2018-10-02 TW TW107134828A patent/TWI795446B/zh active
- 2018-10-03 JP JP2020540680A patent/JP2020536953A/ja active Pending
- 2018-10-03 CN CN201880072989.3A patent/CN111343980B/zh active Active
- 2018-10-03 CA CA3078369A patent/CA3078369A1/en active Pending
- 2018-10-03 AU AU2018345723A patent/AU2018345723B2/en active Active
- 2018-10-03 US US16/753,471 patent/US11382869B2/en active Active
- 2018-10-03 BR BR112020006723-7A patent/BR112020006723A2/pt unknown
- 2018-10-03 IL IL273735A patent/IL273735B2/en unknown
- 2018-10-03 KR KR1020207011696A patent/KR20200062254A/ko not_active Ceased
- 2018-10-03 EP EP18864063.5A patent/EP3691641A4/en active Pending
- 2018-10-03 MX MX2020003044A patent/MX2020003044A/es unknown
- 2018-10-03 WO PCT/US2018/054178 patent/WO2019070864A1/en not_active Ceased
-
2020
- 2020-03-23 ZA ZA2020/01834A patent/ZA202001834B/en unknown
-
2022
- 2022-07-06 US US17/858,471 patent/US20220331264A1/en not_active Abandoned
-
2023
- 2023-08-25 JP JP2023136898A patent/JP7609943B2/ja active Active
- 2023-10-19 US US18/381,849 patent/US20240189252A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536953A5 (https=) | ||
| JP7801518B2 (ja) | 新規な組成物および医薬組成物 | |
| JP6845162B2 (ja) | ケタミン経皮送達システム | |
| US20220395469A1 (en) | Transdermal drug delivery system for ketamine | |
| JP5938612B2 (ja) | 経皮吸収治療システム | |
| RU2408368C2 (ru) | Препараты соли бупропиона с модифицированным высвобождением | |
| TWI704933B (zh) | 右美托咪啶經皮輸送裝置及使用其之方法 | |
| JP6109280B2 (ja) | 活性物質の利用率及び用量精度の高い経皮治療システム | |
| RU2007122410A (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda-рецептора, способ введения такого nmda-антагониста субъекту | |
| BR112015011729B1 (pt) | Sistema terapêutico transdérmico, kit compreendendo o mesmo e método para a preparação do mesmo | |
| CN105764496B (zh) | 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物 | |
| KR102771688B1 (ko) | 바레니클린의 경피 투여를 위한 약학 제제 | |
| CN103432104B (zh) | 一种含有普拉克索的透皮贴剂 | |
| CN104955516B (zh) | 延长丁丙诺啡经皮递送组合物及其使用方法 | |
| TW201206506A (en) | Propynylaminoindan transdermal compositions | |
| JP7049258B2 (ja) | 水性貼付剤 | |
| JP2022530345A (ja) | 経皮治療システム | |
| US20080160068A1 (en) | Method for a Medicinal Combination Treatment, and Medicament Combinations Suitable Therefor | |
| JP2011026227A (ja) | 非含水貼付製剤 | |
| JP2019529332A (ja) | プラミペキソール経皮送達系及びその使用 | |
| TWI745577B (zh) | 經皮吸收製劑 | |
| CN117797130A (zh) | S-氯胺酮经皮组合物及其制备方法和应用 | |
| CN116669714A (zh) | 口服薄膜 | |
| JP2021102573A (ja) | クエン酸フェンタニル含有経皮吸収製剤 | |
| US20190022024A1 (en) | Transdermal patch |